Niknafs, Yashar S.
Han, Sumin
Ma, Teng
Speers, Corey
Zhang, Chao
Wilder-Romans, Kari
Iyer, Matthew K.
Pitchiaya, Sethuramasundaram
Malik, Rohit
Hosono, Yasuyuki
Prensner, John R.
Poliakov, Anton
Singhal, Udit
Xiao, Lanbo
Kregel, Steven
Siebenaler, Ronald F.
Zhao, Shuang G.
Uhl, Michael
Gawronski, Alexander
Hayes, Daniel F.
Pierce, Lori J.
Cao, Xuhong
Collins, Colin
Backofen, Rolf
Sahinalp, Cenk S.
Rae, James M.
Chinnaiyan, Arul M.
Feng, Felix Y.
Article History
Received: 25 May 2016
Accepted: 1 August 2016
First Online: 26 September 2016
Competing interests
: Oncomine is supported by ThermoFisher, Inc. (Previously Life Technologies and Compendia Biosciences). A.M.C. was a co-founder of Compendia Biosciences and served on the scientific advisory board of Life Technologies before it was acquired. D.F.H. receives research funding from Astra-Zeneca, Eli Lilly, Janssen, Pfizer and Puma. He has stock options in OncImmune and in InBiomotion, and he is named as a primary inventor on two patents issued to the University of Michigan, one of which is licensed to Janssen and for which he receives royalties. These patents are not pertinent to the work presented here. The remaining authors declare no competing financial interests.